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E-mail address: salmubarak@kfshrc.edu.sa (S. Al MAim: The objective of the study was to evaluate the effectiveness of scaling and root planing (SRP) and
adjunctive chemotherapy (doxycycline hyclate, 20 mg) on gingival health, speciﬁc cytokines and glyce-
mic control in diabetic subjects.
Methods: Three hundred and forty-six type 1 and 2 diabetic subjects were randomized into four test
groups: (1) one session of SRP at the baseline visit and placebo tablets twice/day, started at the baseline
visit, for 3 months, (2) one session of SRP at the baseline visit, and doxycycline hyclate (20 mg, twice/day)
started at the baseline visit for 3 months, (3) two sessions of SRP, ﬁrst at the baseline visit and second at
the 6 months, with placebo tablets twice/day started at the baseline visit and 6-month visit, for 3 months
at each visit, and (4) two sessions of SRP, ﬁrst at the baseline visit and the second at the 6-month visit,
and doxycycline hyclate 20 mg twice/day, started at the baseline visit and the 6-month visit, for 3 months
at each visit. Venous blood samples were obtained to evaluate TNF-a, IL-1a and glycated hemoglobin
(HbA1c); dental measurements were also included.
Results: HbA1c showed signiﬁcant improvement (P < 0.05) only for subjects with glycated hemoglobin
68.8% within each group, as well as when subjects were combined together. All groups achieved statis-
tically signiﬁcant improvements for most of the dental parameters at follow-up visits (P < 0.05) compared
to the baseline.
Conclusions: Eliminating periodontal inﬂammation may signiﬁcantly reduce glycated hemoglobin levels
for subjects with HbA1c 68.8%; furthermore, SRP and adjunctive therapy improved periodontal inﬂam-
mation in diabetics.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
TheWorld Health Organization (WHO) and International Diabe-
tes Federation (IDF) have predicted that the number of diabetics
will increase signiﬁcantly by the year 2030 to approximately 366
million, an increase of 214% compared to the percentage in 2006
[1]. Diabetes is associated with several complications, and some
types have been linked to a chronic hyperglycemic state. Diabetes
is also frequently associated with pathological changes in the bloodellitus. Published by Elsevier Ltd.
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Ovessel walls [2]. The IDF and American College of Endocrinology
(ACE) recommend HbA1c values of below 6.5%, while the American
Diabetes Association (ADA) recommends that the HbA1c be below
7.0% for most patients [3]. Loe [4] reported that diabetes is a risk
factor for periodontitis, and periodontal disease is the sixth-leading
complication of diabetes [4]. Hyperglycemia appears to trigger a
series of events leading to a higher risk of infection. The association
between diabetes and an increased susceptibility to oral infection,
including periodontal disease, is signiﬁcant [5]. Chronic periodon-
titis is a slowly progressing disease that is primarily the result of an
inﬂammatory response to plaque and calculus accumulation [6]. A
more rapidly progressing clinical presentation of chronic periodon-
titis has been described in diabetic subjects [3,5]. Periodontal dis-
ease may also be an independent predictor of incident type 2pen access under CC BY-NC-ND license.
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tes Care [7]. Studies have shown that diabetic patients with peri-
odontal infection have a greater risk of worsening glycemic
control over time, when compared to diabetic subjects without
periodontitis [8]. The level of speciﬁc inﬂammatory markers
(TNF-alpha) in the gingival crevice ﬂuid has also been related to
the level of glycemic control in diabetic patients [9]. The diabetic
state has also been shown to have an upregulated monocytic
TNF-alpha secretion phenotype which, in the presence of Gram-
negative bacterial challenge, is associated with the expression of
more severe periodontal disease [9].
Several studies addressed the effect of periodontal treatment on
the glycemic control of diabetic subjects [9–14]. However, the role
of periodontal treatment on metabolic control within diabetics is
still controversial [11,12,14–16]. Some studies show that peri-
odontal treatment improves periodontal status in diabetic subjects
[16]. However, other studies report that a further improvement in
metabolic control is achieved when mechanical periodontal treat-
ments and systemic antibiotics are used together [10,17]. Studies
have also demonstrated that the subgingival delivery of doxycy-
cline improves dental parameters, i.e., PPD, CAL, BOP, GI and PI in
subjects with chronic periodontitis, when used in conjunction with
supragingival scaling and dental prophylaxis. Mechanical therapy
is the standard treatment in arresting disease progression and
inﬂammation, and non-surgical care with adjunctive pharmaco-
therapies (such as antimicrobials and/or antibiotics aimed at mod-
ifying the destructive host response) has proved to be of additional
beneﬁt [11,16,18,19].
The aim of this study is to evaluate the effectiveness of scaling
and root planing (SRP) therapy with or without chemotherapy
(doxycycline hyclate, 20 mg) on gingival health, speciﬁc cytokines,
and glycemic control in diabetic subjects.
2. Subject and methods
2.1. Study design
This study is a double-blinded, randomized, placebo-controlled,
12-month multi-center trial. Subject selection was conducted
using eligibility screening following an assessment of periodontal
status during baseline visits, and eligible subjects were given indi-
vidual patient numbers; this was to validate the blinding and ran-
domization analysis. The subjects at each hospital were allocated
numbers which were used to randomize the different groups. This
was achieved by distributing the subject number among the four
test groups by sequentially allocating them to one of four alphabet-
ical codes relating to a test group (i.e., A for group 1, B for group 2, C
for group 3, and D for group 4). The four test groups were: (1) one
session of SRP at the baseline visit only and placebo tablets twice/
day, starting at baseline visit and continuing for 3 months only; (2)
one session of SRP at the baseline visit only and doxycycline hy-
clate (20 mg, twice/day) starting at the baseline visit and contin-
uing for 3 months only; (3) two sessions of SRP, the ﬁrst at the
baseline visit and the second at the 6-month visit and placebo tab-
lets twice/day starting at the baseline visit and the 6-month visit,Table 1
Distribution of different groups based on the treatment.
Months Baseline 3 months
Groups
Group-1 SRP + placebo (for 3 months) –
Group-2 SRP + doxycycline hyclate (for 3 months) –
Group-3 SRP + placebo (for 3 months) –
Group-4 SRP + doxycycline hyclate (for 3 months) –
SRP: scaling and root planing.continuing for 3 months after each visit; and (4) two sessions of
SRP, ﬁrst at the baseline visit and the second at the 6-month visit,
with doxycycline hyclate 20 mg, twice/day starting at the baseline
visit and 6-month visit, continuing for 3 months after each visit
(Table 1). Clinical measurements included the following periodon-
tal parameters: probing pocket depth (PPD), clinical attachment le-
vel (CAL), gingival index (GI), plaque index (PI) and bleeding on
probing (BOP). Fasting venous blood samples (20 mL) were ob-
tained from the antecubital vein by venipuncture using a 27-G but-
terﬂy needle in the morning between 8:00 a.m. to 10:30 a.m. for
the laboratory analysis of cytokines [Tumor Necrosis Factor alpha
(TNF-a), Interleukin-1 alpha (IL-1a)] and to evaluate glycated
hemoglobin (HbA1c) in all subjects. It should be mentioned here
that the examiners as well as the dental hygienist in the different
hospital were all blinded to the assigned treatment. Subjects were
also blinded to the prescribed medication (doxycycline hyclate,
20 mg or placebo).
2.2. Study population
This study was conducted on 369 diabetic subjects registered at
Riyadh Armed Forces Hospital, King Faisal Specialist Hospital and
Research Center, King Abdul Aziz Medical City, Naval Base Hospital
and Sultan Bin Adulaziz Humanitarian City, Riyadh, Saudi Arabia.
The subjects were recruited from the above hospitals during their
routine dental follow-up appointments. All subjects who were
willing to participate in this research were asked to sign an in-
formed consent agreement to participate in this study. The study
was approved by the Research and Ethics Committee of the ﬁve in-
volved hospitals and the study registered with International Stan-
dard Randomized Controlled Trial Number (ISRCTN-11742127).
Twenty-three subjects did not continue at several intervals during
the 12 months of the study, for reasons that violated the inclusion
criteria – i.e., taking an antibiotic during the study period, extrac-
tion of tooth/teeth, minor or major surgical intervention during
the study period, or due to loss of contact information. It should
be mentioned here that those who failed to show up at any time
point after the baseline visit or failed to show at the last visit
(12 months) were also completely excluded from the study. A total
of 346 subjects continued until the end of the study. Inclusion cri-
teria were as follows: age range between 18 and 65 years old; dia-
betes identiﬁed as type 1 or 2; diabetes diagnosed P1 year;
diabetes under control by oral hypoglycemic agent or insulin or
both; constant type and dose of diabetic medication administered
for the previous 6 months; and good physical condition with no
serious medical conditions or transmittable diseases – i.e., malig-
nant disease; active hepatitis; freedom from any cardiac condition
that would require antibiotic prophylaxis prior to SRP; a minimum
of 18 remaining natural and non-capped teeth; a minimum of six
sites in a minimum of two different quadrants with PPD P5 mm
but 68 mm; no treatment with SRP in the 6 months prior to the
baseline visit; visible supragingival calculus in a minimum of four
teeth in two different quadrants; the absence of orthodontic bands
and brackets and/or dental appliances that would compromise the
scored index; no use of antibiotics within the 3 months prior to the6 months 9 months 12 months
– – –
– – –
SRP + placebo (for 3 months) – –
SRP + doxycycline hyclate (for 3 months) – –
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nursing.2.3. Assessment procedures
Three trained, precalibrated examiners (periodontists) were
allocated among the four centers. They were assigned to perform
clinical assessments for all subjects throughout the study. Inter-
and intra-examiner variability in the dental examination criteria
were tested by performing duplicate examinations on 16 randomly
selected subjects among the four centers at the baseline visit. The
percentages of agreement were 93% for PPD, 87% for CAL, 94% for
BOP, 91% for PI, and 88% for GI. An assessment for the each subject
was conducted at baseline and at 3, 6, 9 and 12 months. Clinical
dental measurements included PPD, CAL, BOP, GI, and PI; they
were collected at the baseline, and at 3, 6, 9 and 12 months.
Each subject received full mouth supragingival and subgingival
debridement using ultrasonic and hand instrumentation. This
treatment was undertaken at one or two different visits, with a
maximum of seven days between the ﬁrst and second visits, by
four trained dental hygienists, who were recruited solely for this
purpose, at the four centers. Dental hygiene aids were provided
for the subjects – i.e., toothbrush and toothpaste at the baseline
visit. Written oral hygiene instructions were given to all subjects
within the different treatment groups at each session, including
appropriate teeth brushing technique (Bass method) [20] and dem-
onstration of the proper use of inter dental brushes and dental
ﬂoss. The Bass method calls for up and down strokes on the sides
of the teeth with back and forth strokes on the tops of teeth.
PPD, CAL, and BOP were measured on all existing teeth based on
the above inclusion criteria at the six sites (mesio-buccal, med-
buccal, disto-buccal, mesio-lingual, med-lingual and disto-lingual)
using pressure-sensitive periodontal probes ( Florida Probe Cor-
poration, 3700 NW 91st Street, C-100, Gainesville, FL 32606,
USA). Four teeth within a minimum of two quadrants were se-
lected, based on the criteria mentioned earlier for the follow-up
examination at the 3-, 6-, 9- and 12-month visits. CAL was mea-
sured for teeth using the cemento-enamel junction (CEJ) as a refer-
ence point. GI [21], PI [22] were measured for all teeth on the facial,
lingual, mesial and distal surfaces excluding the third molars. GI
scores were as follows: 0 = normal gingiva, no inﬂammation, dis-
coloration or bleeding; 1 = mild inﬂammation, slight color change,
mild alteration of gingival surface, no bleeding; 2 = moderate
inﬂammation, erythema and swelling, bleeding on probing or
when pressure was applied; and 3 = severe inﬂammation, ery-
thema and swelling, tendency to spontaneous bleeding, perhaps
ulceration. The PI scores were as follows: 0 = no plaque; 1 = thin
ﬁlm of plaque at the gingival margin, visible only when scraped
with an explorer; 2 = moderate amount of plaque along the gingi-
val margin, which can be seen by the naked eye; 3 = heavy plaque
accumulation at the gingival margin; interdental space ﬁlled with
plaque. BOP was measured for all teeth at the six sites for each
tooth, and rated as follows: 0 = no bleeding within 15 s after prob-
ing, or 1 = bleeding within 15 s after probing. The HbA1c test wasTable 2
Distribution of subjects in respective study groups.
Group Subjects distribution Gender
Male Femal
1 98 41 57
2 93 44 49
3 75 34 41
4 80 42 38
Total 346 161 185performed at baseline and during the 3-, 6-, 9- and 12-month
visits.
2.4. Cytokines analysis
A commercially available human interleukin enzyme-linked
immunosorbent assay kit (Duo Set, ELISA Development System,
UK) was used to determine the effect of the periodontal treatment
on TNF-alpha, IL-1 alpha. The standards and samples were incu-
bated in a 96-well polystyrene microplate coated with Capture
Antibodies TNF-alpha, and IL-1 alpha, respectively. The interleu-
kins in the samples were bound to the wells, and the other compo-
nents of the samples were removed by washing and aspiration. The
interleukins were detected by biotinylated goat anti-human anti-
bodies. The amount of peroxidase bound to each well was mea-
sured by adding a tetramethylbenzidine (TMB) substrate. The
reaction was quenched by the addition of 2 N sulphuric acid. The
plate was read at 450 nm. The concentration of the interleukins
in the serum samples was calculated by interpolation from a stan-
dard curve.
2.5. Statistical analysis
Statistical analyzes were performed on the data obtained from
all subjects who completed the study and had no substantial pro-
tocol violations. All the available data from these subjects were
analyzed, and no imputations were carried out for missing data.
The results of dental parameters (PPD, CAL, GI, PI, and BOP), cyto-
kines (TNF-a and IL-1a) and HbA1c measurements were analyzed
using one-way analysis of variance (ANOVA). The Tukey–Kramer
multiple comparisons test was used for comparisons among test
groups. P-values <0.05 were assumed to be statistically signiﬁcant.3. Results
The age, gender and distribution of patients to the different
study groups are illustrated in Table 2. A total of 346 subjects con-
tinued until the end of the study. 33 subjects were deﬁned as type
1 diabetics out of the total sample; the remaining were deﬁned as
type 2 diabetics.
3.1. HbA1c (%)
Group 1 showed a marked but insigniﬁcant reduction at 3 and
6 months (8.89 ± 0.34% and 8.97 ± 0.48%, respectively). However,
it rebound to a higher (but statistically insigniﬁcant) level than
that recorded at the baseline visit (9.87 ± 0.33% and 9.90 ± 0.52%,
respectively). Group 2 showed the same trend as group 1, and
the changes were not signiﬁcant. Group 3 did not show signiﬁcant
changes at the 3-, 6-, 9-, and 12-month visit (9.05 ± 0.39%,
8.58 ± 0.54%, 8.82 ± 0.42%, and 8.90 ± 0.53%, respectively) as com-
pared to the baseline value (8.87 ± 0.29%), with no statistical differ-
ence between the different follow-up visits. Compared to the
baseline value the group 4 showed a slight increase, with noMean age (years) Types of diabetes
e Type-1 Type-2
51 ± 6 9 89
48 ± 5 9 84
47 ± 4 7 68
43 ± 6 8 72
47 ± 6 33 313
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(9.14 ± 0.30%, 9.20 ± 0.28%, and 9.78 ± 0.38%, respectively) except
9-month visit (9.03 ± 0.35%). However, no signiﬁcant differences
were observed between the different groups (Fig. 1a).
A scaled-down statistical analysis of HbA1c for those subjects
with baseline readings 68.8% within each individual treatment
group showed a steady but continuous (and signiﬁcant) numeric
reduction associated with an improvement in periodontal health
(Fig. 1b). Interestingly, this signiﬁcant reduction was observed
when those subjects with HbA1c 68.8% (n = 132) within the four
groups combined together (Fig. 1c).
3.2. TNF-a (pg/ml)
The results showing the effect of different treatments on TNF-
alpha are described in Table 3. There were no signiﬁcant changes
at the different time points within the four examination groupsFig. 1a. HbAlc (%) level within different treatment groups. Values are mean ± SEM,
*P-values versus base line, Tukey–Kramer multiple comparisons test. Groups
compared by Tukey–Kramer multiple comparisons test: $ 1 vs. 3 (P < 0.05), f 2 vs. 4
(P < 0.05).
Fig. 1b. Periodontal treatment on HbAlc (%) (=<8.8). Values are mean ± SEM,
*P-values versus base line, Tukey–Kramer multiple comparisons test, *P < 0.05,
**P < 0.01. Groups compared by Tukey–Kramer multiple comparisons test:  1 vs. 4
(P < 0.05).
Fig. 1c. Periodontal treatment on HbA1c (%) (=<8.8). For all groups.(1, 2, 3, and 4) or between the different groups (Table 3) except
group 3 at 6-month and group 4 at 9-month visit compared to
the baseline readings.
3.3. IL-1a (pg/ml)
The results showing the effect of different treatments on TNF-
alpha are described in Table 3. There were no signiﬁcant changes
at the different time points within the four examination groups
(1, 2, 3, and 4) or between the different groups (Table 3) except
group 3 at 12-month and group 4 at 12-month visit compared to
the baseline readings.
3.4. Clinical periodontal parameters
3.4.1. Dental indices
Changes within the periodontal parameters are illustrated in
Table 4. It should be noted here that there were signiﬁcant changes
in PPD, PI, GI, and BOP for all groups, as compared to the baseline in
the follow-up visits; such changes were not observed for CAL
(Table 4).4. Discussion
Adult periodontitis is a chronic inﬂammatory condition, charac-
terized by acute episodes of periodontal destruction occurring in a
susceptible host. The successful long-term management of peri-
odontitis may require an integrated and tailored treatment that en-
sures that mechanical debridement will help in protecting the
susceptible host and eliminating the causes of periodontitis. Previ-
ous studies have demonstrated that the subgingival delivery of
doxycycline improves dental parameters, i.e., PPD, CAL, BOP, GI
and PI in subjects with chronic periodontitis, when used in con-
junction with supragingival scaling and dental prophylaxis
[14,19,23]. Extending the longevity of teeth and reducing patholog-
ical, microbial anaerobic bacteria are the important reasons for
performing periodontal therapy, to stabilize periodontal health
within susceptible individuals and to prevent further loss of peri-
odontal support [24].
Many studies have addressed the effect of periodontal treat-
ment on the glycemic control of diabetic subjects [10–14,16]. The
outcome of these studies is controversial. Some studies have
shown that periodontal treatment has made little – if any-clinical
improvement to glycemic control within diabetic subjects [10,16].
However, other studies show that periodontal treatment improves
glycemic control in diabetic subjects [16], and report that there are
further signiﬁcant numeric as well as clinical improvements
achieved in metabolic control when mechanical periodontal treat-
ments and systemic antibiotics were combined together [10,17]. A
reduction in glycated hemoglobin was noted in type 1 diabetes
subjects following periodontal therapy, combined with systemic
antibiotic treatment [17]. Similar results were found in type 2 dia-
betes subjects using systemic doxycycline [10]. It should be men-
tioned that in the present study, there were no signiﬁcant
changes to be observed in HbA1c; in addition, such changes were
not equal for all groups within the study population or for subjects
within each group. This is in agreement with previous studies,
which show that mechanical periodontal treatment demonstrates
an improvement in periodontal status without changes in glycemic
control [10,14,19,25]. However, other studies have reported
improvements in periodontal status and glycemic control when
mechanical treatment and systemic antibiotics are included
[10,19]. Williams and Mahan [17] also demonstrate that periodon-
tal therapy improves metabolic control, as indicated by reduced
insulin requirements and reductions in the blood glucose level.
Table 3
Effect of different treatments on IL-1 alpha (pg/ml) and TNF-alpha (pg/ml).
Periodontal parameter Group Baseline 3 months 6 months 9 months 12 months
IL-1 alpha (pg/ml) 1 3.16 ± 0.43 3.42 ± 0.42 2.85 ± 0.39 2.74 ± 0.37 2.83 ± 0.41
2 3.02 ± 0.37 3.16 ± 0.37 2.97 ± 0.37 2.73 ± 0.32 2.72 ± 0.42
3 3.08 ± 0.27 3.1 ± 0.43 2.63 ± 0.39 3.05 ± 0.37 2.46 ± 0.36*
4 3.04 ± 0.43 3.16 ± 0.38 2.57 ± 0.41 2.89 ± 0.38 2.35 ± 0.36*
TNF-alpha (pg/ml) 1 12.06 ± 2.43 12.86 ± 2.54 10.28 ± 2.16 12.1 ± 2.14 11.02 ± 2.34
2 11.87 ± 2.12 12.42 ± 2.67 11.96 ± 2.42 10.73 ± 2.22 9.87 ± 2.72
3 11.06 ± 1.73 12.96 ± 2.12 9.07 ± 2.02* 11.06 ± 2.87 11 ± 2.65
4 11.4 ± 2.45 12.06 ± 2.03 10.13 ± 2.97 8.26 ± 2.83* 10.24 ± 2.24
Values are mean ± SEM.
* P-values versus base line, Tukey–Kramer multiple comparisons test, *P < 0.05. Groups compared by Tukey–Kramer multiple comparisons test:  1 vs. 4 (P < 0.05),  2 vs. 3
(P < 0.05).
Table 4
Effect of different treatments on periodontal parameter.
Periodontal parameter Group Baseline 3 months 6 months 9 months 12 Months
PI (mean) all teeth 1 2.51 ± 0.08 1.71 ± 0.14*** 1.87 ± 0.13*** 1.95 ± 0.15*** 1.46 ± 0.21***
2 2.3 ± 0.1 1.53 ± 0.13*** 1.82 ± 0.12** 1.46 ± 0.16*** 1.69 ± 0.16**
3 2.15 ± 0.1 1.5 ± 0.13*** 1.59 ± 0.16** 1.4 ± 0.18***$ 1.51 ± 0.22*
4 2.11 ± 0.1 1.66 ± 0.13** 1.55 ± 0.13** 1.8 ± 0.13 1.64 ± 0.18*
GI (mean) all teeth 1 2.38 ± 0.07 1.49 ± 0.12*** 1.5 ± 0.12*** 1.78 ± 0.13*** 1.64 ± 0.2***
2 2.15 ± 0.11 1.23 ± 0.12*** 1.55 ± 0.1*** 1.34 ± 0.16*** # 1.35 ± 0.21***
3 2.06 ± 0.11 1.27 ± 0.12*** 1.39 ± 0.13*** 1.4 ± 0.17***$ 1.34 ± 0.25***
4 2.06 ± 0.1 1.47 ± 0.13*** 1.53 ± 0.12*** 1.64 ± 0.13*** 1.27 ± 0.23***
PPD (mm) experimental teeth only 1 4.06 ± 0.13 3.2 ± 0.13*** 2.94 ± 0.16*** 3.16 ± 0.26*** 2.69 ± 0.25***
2 3.9 ± 0.14 2.88 ± 0.15*** 3.05 ± 0.17*** 2.82 ± 0.22*** 2.4 ± 0.2***
3 3.86 ± 0.18 2.7 ± 0.14***$ 2.74 ± 0.16*** 2.63 ± 0.22*** 2.46 ± 0.35***
4 3.92 ± 0.13 2.86 ± 0.15*** 2.94 ± 0.15*** 2.99 ± 0.16*** 2.29 ± 0.27***
CAL (mm) experimental teeth only 1 5.58 ± 0.23 4.92 ± 0.22 4.87 ± 0.25 4.8 ± 0.31 5.25 ± 0.29
2 5.01 ± 0.2 4.43 ± 0.23 4.6 ± 0.25 4.47 ± 0.3 4.37 ± 0.25
3 5.32 ± 0.27 4.42 ± 0.24* 4.53 ± 0.25 4.48 ± 4.41 4.89 ± 0.29
4 4.96 ± 0.18 4.45 ± 0.19 4.64 ± 0.2 4.65 ± 0.17 3.83 ± 0.18 
BOP (%) all teeth 1 75.8 ± 3.3 35.2 ± 4.5*** 31.2 ± 5.3*** 34.8 ± 5.8*** 5.25 ± 6***
2 75.01 ± 3.4 24.1 ± 4.2*** 31.2 ± 4.5*** 28 ± 5.4*** 15.9 ± 6.4***
3 61.7 ± 4.8 21.9 ± 3.9*** 21.4 ± 4.2*** 24.3 ± 6.4*** 20.9 ± 8.4***
4 65.2 ± 4.7 32.5 ± 5.3*** 24.6 ± 4.2*** 28.4 ± 5.9*** 15.1 ± 6.1***
PPD – probing pocket depth, CAL – clinical attachment level, GI – gingival index, PI – plaque index, BOP – bleeding on probing.
Values are mean ± SEM, *P-values versus base line, Tukey–Kramer multiple comparisons test, *P < 0.05, **P < 0.01, ***P < 0.001. Groups compared by Tukey–Kramer multiple
comparisons test: # 1 vs. 2 (P < 0.05), $ 1 vs. 3 (P < 0.05),  1 vs. 4 (P < 0.05).
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with baseline readings 68.8% within each individual treatment
group showed a steady but continuous (and signiﬁcant) numeric
reduction associated with an improvement in periodontal health
(Fig. 1b). Interestingly, this signiﬁcant reduction was observed
when those subjects with HbA1c 68.8% (n = 132) within the four
groups are combined together (Fig. 1c).
In addition, there was a statistically signiﬁcant improvement at
each time point when compared to the baseline reading; also,
when the HbA1c value became higher within that range (68.8%),
the reduction was more noticeable. This observation may be ex-
plained by the impact of the local oral infection and periodontal
inﬂammation, i.e., swelling, bleeding and calculus accumulation
on the underlying systemic conditions may be systemically effec-
tive, and add numerical impact and value, which could further pro-
voke an underlying inﬂammatory response when HbA1c is higher
within that range (68.8%) [4,15] and enhance the glycemic distur-
bance. In addition, when combined with high HbA1c levels within
the range 68.8%, this may synergistically raise the HbA1c level
within this group of diabetic patients. Therefore, the improvement
may be numerically noticeable, due to the improvement in previ-
ously mentioned local factors, which may contribute to the sys-
temic improvement maintained by hypoglycemic medications.
On the other hand, when the glycemic level is uncontrolled (i.e.,>9%), which may occur because of several major systemic factors
(i.e., inappropriate dose of hypoglycemic medications, uncon-
trolled diabetes), the inﬂuence of periodontal therapy is deﬁned
hereby as local factors, i.e., improvement in periodontal infection
will be diminished, and may not enhance improvement compared
to the underlying compromised systemic condition (poor glycemic
control). Also, it was noticeable that when the HbA1c level ap-
proached near to the normal range (6.5%), such associations be-
came weak or/and insigniﬁcant. This complex phenomenon may
be explained hypothetically by the fact that when the glycated
hemoglobin level is relatively controlled (6.5%), any improve-
ment within the local oral environment (measured by periodontal
indices) may have minimal impact, if any, on the systemic
improvement measured by HbA1c. Thus, periodontal therapy
may enhance improvement near the normal range of glycated
hemoglobin for those subjects under good diabetic control. The
evidence and reasoning described herein may improve the under-
standing of the signiﬁcant conﬂict and controversy that resulted
from previous studies, as most of those studies did not establish
a clear and appropriate link to the trends and levels of glycated
hemoglobin. Further studies may be needed to test these ﬁndings.
Studies have shown that TNF has a broad range of biological ef-
fects, including the stimulation of bone resorption [26]. The pres-
ent study shows that there is a general trend toward a slight
S. Al Mubarak et al. / International Journal of Diabetes Mellitus 2 (2010) 158–164 163mean reduction among the four groups when compared to the
baseline measurements. However, this change is not signiﬁcant
when comparing different groups, or when comparing any of the
follow-up time points to the baseline reading (Table 3). This may
be explained by the fact that the improvement of certain inﬂam-
matory mediators (i.e., TNF-a) is sensitive to the given treatment
and that this effect may not last long as such levels will rebound
within 24 h [27]. Therefore, because periodontal inﬂammation is
a chronic disease that recurs in most of the affected subjects at dif-
ferent levels after the given treatment, the level of TNF-amay have
reduced further after the prescribed treatment but rebound before
the next evaluation visit.
The potential role of IL-1 in periodontal tissue destruction in-
volves negative effects on periodontal ligament cells [28]. IL-1 has
been shown to have strong stimulatory effects on increased bone
resorption and inhibitory effects on bone formation [28]. Other
studies have clearly demonstrated that interleukin-1 is a potent
stimulator of bone resorption and that this effect is mediated
via prostaglandin E2 (PGE2) [29]. The present study shows that
all groups achieved a mean improvement in IL-1a by the end of
the study, compared to baseline levels (Table 3). However, none
of the groups achieved any clinical or statistical signiﬁcance or
added advantage when compared to each other. In comparing
the results of this study to those of previous studies [30,31], it
is suggested that SRP reduces TNF-a and IL-1a levels in the stud-
ied population. However, the reductions found were not statisti-
cally signiﬁcant.
In the present study, the severity of periodontal disease mea-
sured by dental indices (PPD, CAL, GI, PI, and BOP) was approxi-
mately within the same range at baseline, with no signiﬁcant
difference among the four groups (Table 4). Clinical improvement
was statistically signiﬁcant in most of the clinical periodontal
parameters (PPD, GI, PI, and BOP) within the four treatment groups
at the 3-, 6-, 9-, and 12-month visits (Table 4). This is in accordance
with the results of several previous studies [32,33]. The ﬁndings
indicate that (1) periodontal maintenance therapy, including scal-
ing and root planing and tooth debridement, when given periodi-
cally to diabetics, and (2) oral hygiene instruction, which was
given at each recall visit, resulted in markedly improved oral hy-
giene conditions for all treatment groups (Table 4), a result that
supports the ﬁndings of earlier studies [32,33].
Therefore, it is conﬁrmed that scaling and root planing (SRP) has
a signiﬁcant and beneﬁcial effect on periodontal health in these
diabetic subjects, and reduced tissue breakdown. However, adjunc-
tive therapy (groups 2 and 4) had numeric but not statistically sig-
niﬁcant clinical advantages. The present study shows that although
there is a general trend toward improvement (as measured by den-
tal indices at each follow-up visit), group 4 subjects had a statisti-
cally signiﬁcant improvement at the 12-month visit, compared to
the baseline level. This is in agreement with existing research
[34] and may be due to the efﬁcacy of the repeated sessions of
SRP, as well as the repeated adjunctive chemotherapy treatment
(doxycycline hyclate, 20 mg) that might help in reducing gingival
inﬂammation. It is consistent with earlier reports describing the
efﬁcacy of regular and low-dose tetracyclines, such as minocycline
and low-dose doxycyline [35]. The beneﬁcial effects of adjunctive
chemotherapy (doxycycline hyclate, 20 mg), along with SRP (group
2), may help in reducing gingival inﬂammation. Accordingly, our
observation needs further validation to provide better evidence
in this regard. Whether there is a cut-off point in the HbA1c level
that can be improved by treating local factors, i.e., periodontal dis-
ease is an interesting point to discuss in future studies. Further
studies are needed to enhance our understanding of the role of
periodontal treatment in diabetes mellitus. In conclusion to this
study, the present results suggest that the improvement in peri-
odontal inﬂammation measured by periodontal indices may leadto a signiﬁcant improvement in the glycated hemoglobin level
for subjects with HbA1c 68.8%.Contribution
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